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Travelsted: Monkeypox: Facts for Faith Community Nurses

Faith community nurses provide services to diverse populations and should be aware of
the recent outbreak of monkeypox. The multi-country outbreak was first reported to the World
Health Organization (WHO) on May 13, 2022 (WHO, 2022b). An outbreak is defined as one
reported case of monkeypox in a non-endemic country. What makes this situation unusual and
concerning is that the cases were reported in non-endemic countries with most having no
established travel links to endemic areas. Previous human outbreaks outside of Africa were
linked to international travel to non-endemic areas (Centers for Disease Control and Prevention
[CDC], 2022a). The vast majority of monkeypox cases in the United States have been diagnosed
in gay, bisexual, and other men who have sex with men (MSM) (CDC, 2022i; WHO 2022b).
What is Monkeypox?
Monkeypox was first discovered in a colony of research monkeys in 1958 with the first
human case reported in 1970 (CDC, 2022a). Monkeypox caused by the monkeypox virus of the
Orthopoxvirus genus is milder than smallpox and is rarely fatal (WHO, 2022a). Transmission
occurs through close contact to lesions, body fluids, respiratory droplets, fabrics (clothing or
bedding) or objects of an individual infected with monkeypox (WHO, 2022b).
The incubation period ranges from 5-21 days with symptoms of monkeypox appearing
within 3 weeks of exposure to include flu-like symptoms of fever, headache, lymphadenopathy,
backpain, muscle aches, and weakness (CDC, 2022e; WHO 2022a). Lymphadenopathy is the
distinguishing characteristic of monkeypox when compared to similar diseases such as smallpox,
chickenpox, and measles. The rash appears 1-4 days after the appearance of fever and is
concentrated on the face, hands, feet, and genitalia with the lesions developing in a sequential
fashion (macules, papules, vesicles, pustules, scabs) (WHO, 2022b). The virus is usually selflimiting lasting 2-4 weeks and can be transmitted until the rash is completely healed with a fresh
layer of skin (CDC, 2022e). The 2022 outbreak has an atypical presentation with a rash localized
to the oral and genital areas accompanied by painful regional lymphadenopathy (WHO, 2022b).
What to Do if Monkeypox is Suspected?
Providers are encouraged to test individuals suspected of monkeypox who present with
new onset of rash specifically if it is deep-seated, firm, well-circumscribed and umbilicated
(CDC, 2022b; CDC,2022f). Providers should also test those patients presenting with at least one
of the established epidemiologic criteria (see Table 1) (CDC, 2022b). Initial monkeypox testing
involves obtaining two lesion specimens from different locations on the body (CDC, 2022h).
Personal protective equipment (PPE) should be worn by those examining suspected individuals
and those obtaining diagnostic specimens. Specimen testing is available at CDC Laboratory
Response Network (LRN) laboratories or at authorized commercial laboratories (CDC, 2022h;
FDA, 2022).
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Table 1
Monkeypox 2022: Epidemiologic Criteria
EPIDEMIOLOGIC CRITERIA: Within 21 days of illness onset
Reports having contact with a person or people with a similar appearing rash or who received
a diagnosis of confirmed or probable monkeypox OR
Had close or intimate in-person contact with individuals in a social network experiencing
monkeypox activity, this includes men who have sex with men (MSM) who meet partners
through an online website, digital application (“app”), or social event (e.g., a bar or party) OR
Traveled outside the US to a country with confirmed cases of monkeypox or where
Monkeypox virus is endemic OR
Had contact with a dead or live wild animal or exotic pet that is an African endemic species or
used a product derived from such animals (e.g., game meat, creams, lotions, powders, etc.)
EXCLUSION CRITERIA: A case may be excluded as a suspect, probable, or confirmed
case if:
An alternative diagnosis can fully explain the illness OR
An individual with symptoms consistent with monkeypox does not develop a rash within 5
days of illness onset OR
A case where high-quality specimens do not demonstrate the presence of Orthopoxvirus or
Monkeypox virus or antibodies to orthopoxvirus
Note. Adapted from “Monkeypox: Case Definitions for Use in the 2022 Monkeypox Response,” by CDC, 2022,
https://www.cdc.gov/poxvirus/monkeypox/clinicians/case-definition.html

The WHO and CDC recommend antiviral treatment be considered for severe cases and
those individuals at increased risk of adverse outcomes (CDC, 2022d; WHO, 2022a). Severity of
the disease is related to exposure, vaccination status, the underlying health status of the
individual, concurrent illnesses, and comorbidities. Severe cases are more common in those with
underlying immune deficiency, children younger than 8 years of age, a current or history of
atopic dermatitis or other active exfoliative skin condition, complications, and pregnant or
breastfeeding women (CDC, 2022d). Secondary infections, pneumonia, sepsis, encephalitis, and
loss of vision due to corneal infections are possible complications of monkeypox (WHO, 2022a).
There is no approved treatment for monkeypox; however, tecovirimat (TPOXX), an
antiviral medication approved by the FDA for the treatment of smallpox in adults and children,
has received expanded access for the treatment of monkeypox (CDC, 2022g; FDA, 2022). The
safety and efficacy for the treatment of monkeypox in humans with TPOXX has not been
established. TPOXX is available through the Strategic National Stockpile and clinicians should
request the medication from their state/regional health departments (CDC, 2022g). Providers can
contact the CDC Emergency Operations Center (770-488-7100) for urgent clinical consultations.
Public Health Response
As of August 30, 2022, the CDC reported 18,101 cases of monkeypox in the United
States (CDC, 2022c). All U.S. states including the District of Columbia and Puerto Rico have
confirmed cases. The JYNNEOS vaccine to prevent monkeypox and smallpox was approved by
the FDA in 2019 (FDA, 2022a; FDA, 2022b). JYNNEOS is a two-dose subcutaneous vaccine
administered 28 days apart and indicated for use in adults 18 years of age and older at high risk
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of infection. On August 9, 2022, due to the emerging public health crisis and the need to increase
availability of vaccine, the FDA issued an emergency use authorization (EUA) to allow
administration of the vaccine by intradermal injection at one fifth the original dose increasing the
availability of vaccine (FDA, 2022b). The EUA also allows for subcutaneous use in individuals
under the age of 18 at high risk of monkeypox infection.
On August 8, 2022, the WHO convened a group of experts to rename the monkeypox
disease and virus variants (Center for Infectious Disease Research and Policy, 2022; WHO,
2022c). The Congo basin (Central African) variant was renamed clade one (I) and the West
African clade was renamed clade two (II). Clade II was further delineated to clade IIa and clade
IIb. Clade IIb is the variant associated with the global outbreak of 2022. The WHO is collecting
new name proposals for the monkeypox disease, and the International Committee on the
Taxonomy of Viruses (ICTV) is in the process of renaming the monkeypox virus.
Conclusion
The 2022 monkeypox outbreak is a public health concern (CDC, 2022i). Although most
confirmed cases are in the MSM population any person who exposed to monkeypox is at risk for
developing disease. As the number of cases in the U.S. continue to grow, faith community nurses
need to be aware of the screening criteria, available treatment for severe cases, and availability of
vaccine for prevention.
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